Evaluation of ambulatory antibiotic use in Hungary using drug-specific quality indicators

Abstract

In quantity Hungary an ambulatory antibiotic use resembles to Scandinavian countries while it mimics antibiotic consumption patterns of southern countries.

In vitro antibiotic susceptibility profile of Clostridium difficile excluding PCR ribotype 027 outbreak strain in Hungary

“…In Hungary, between 1996 and 2010, the ambulatory antibiotic use has been changed dramatically in structure. Ratios of consumption of broad to narrow spectrum beta-lactams, and macrolides increased eight-fold, while in the case of fluoroquinolones, the consumption was tripled [4]. However in quantity, the antibiotic consumption in Hungary was similar to the Scandinavian countries and the consumption has been considered to be low among European countries.…”

Hazai kórházi antibiotikum-alkalmazás az elmúlt két évtizedben (1996–2015)

“…Az egyes penicillincsoportok vonatkozásában: míg a své-dek és norvégek szűk spektrumú penicillineket alkalmaztak (ATC: J01CE és J01CF) több mint 50%-os arányban 2014-ben, addig az adatokat jelentő európai országok közül nálunk alkalmaztak ezekből a penicillinekből a legkevesebbet (2015-ben 1% alatti volt a penicillincsoporton belüli részesedésük). Az ambuláns szektorban hasonló átrendeződésnek voltunk tanúi [10,11].…”

“…Hasonlókat tapasztaltunk az ambuláns ellátásban is [11], oka nem ismert. Hazánk fluorokinolonfelhasználása közepes az európai országok rangsorában, a fluorokinoloncsoport kórházi antibiotikum-fogyáson belüli részesedése tekintetében viszont az egyik legmagasabb (6. ábra).…”

Evaluation of the Hungarian ambulatory antibacterial use in urinary tract infections with different methods

“…There are some international [69,[117][118][119][120][121][122] articles and only a few Hungarian [75,123] works dealing with the quality of antibiotic consumption in the ambulatory care, even with prescribing quality indicators [68,75,[124][125][126]. Another important field in connection with the quality of antibiotic use is the adherence of treatment practice to the national clinical guidelines.…”

“…Consumption of antibacterials for systemic use in EU/EEA countries, 2012 (expressed as DDD per 1 000 inhabitants and per day) [25] The use of quinolones is relatively high in Europe, it was in the third quartile among the EU countries in 2009, the ambulatory antibiotic consumption fourth quartile similarly to the South-European countries. The consumption of quinolones tripled between 1996 and 2012 in Hungary in ambulatory care (0.64 vs. 1.91 DDD per 1000 inhabitants per day) and shared more than 10% from the ambulatory antibiotic consumption [26]. Figure 2 demonstrates the consumption of quinolones for systemic use in the ambulatory care in 2012.…”